Experimental Design in Clinical 'Omics Biomarker Discovery

Area of Science:

• Biomedical research
• Translational science
• Biomarker discovery

Background:

• Clinical omics biomarker discovery requires rigorous experimental design to ensure reliable results.
• Bias in experimental design can compromise the accuracy and validity of biomarker findings.
• Translational research necessitates robust methods for identifying and validating potential biomarkers.

Purpose of the Study:

• To highlight critical issues in the experimental design of clinical omics biomarker discovery.
• To provide guidance on avoiding bias and obtaining true quantities in biochemical analyses.
• To improve sample selection strategies for enhancing the likelihood of answering clinical questions.

Main Methods:

• Defining clear clinical aims and endpoints.
• Understanding and accounting for result variability.
• Implementing randomization and appropriate sample size calculations.
• Utilizing statistical power considerations.
• Incorporating clinical data into sample selection to mitigate confounding factors.

Main Results:

• Experimental design flaws can lead to biased results and hinder biomarker discovery.
• Proper sample selection, informed by clinical data, is crucial for avoiding statistical analysis surprises.
• Addressing variability, randomization, and sample size enhances the reliability of omics data.

Conclusions:

• Adherence to sound experimental design principles is paramount for successful clinical omics biomarker discovery.
• Improved study design increases the validity and potential of future biomarker candidate findings.
• This tutorial serves as a guide for preclinical and translational biomarker research.